- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request | ||
| 16.04. | Report: Europe leads in number of clinical trials for cystic fibrosis, North America for AML | ||
| 16.04. | J&J CEO says M&A strategy 'will continue' after medtech megadeals | ||
| 16.04. | PacBio plots budget cuts after DNA sequencing revenue shortfalls | ||
| 16.04. | Takeda inks sweet $1.2B+ deal with Kumquat for immuno-oncology program | ||
| 16.04. | Cullinan Oncology rebrands, halts lymphoma trial to reflect autoimmune refocus | ||
| 15.04. | FDA delivers de novo clearances to two novel antibacterial implant coatings | ||
| 15.04. | Butterfly Network expands maternal ultrasound efforts across Africa | ||
| 15.04. | Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond | ||
| 15.04. | Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacy | ||
| 15.04. | Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits | ||
| 15.04. | MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD | ||
| 12.04. | Roche picks up Prenosis' newly cleared sepsis AI tool for distribution | ||
| 12.04. | Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts | ||
| 12.04. | Portage Biotech hints at potential closure as it halts programs, hunts for strategic options | ||
| 12.04. | Illumina gets go-ahead from European Commission to part ways with Grail | ||
| 12.04. | Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis | ||
| 12.04. | Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing | ||
| 11.04. | Peak Rock Capital takes a bite out of Steris with $787M dental business deal | ||
| 11.04. | Alzheimer's blood test from Roche & Eli Lilly nabs FDA breakthrough tag | ||
| 11.04. | Double autoimmune acquisitions as Century, Eliem each pick up peers | ||
| 11.04. | Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader | ||
| 11.04. | AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors' potential in preclinical data | ||
| 10.04. | Nearly a week after pulling Relyvrio, Amylyx to engage regulators about the drug's path in another rare disease | ||
| 10.04. | Philips plots return to US sleep apnea market after final consent decree in CPAP recall |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
